PSF inhibitor No. 10-3 is a small molecule inhibitor of RNA-binding protein PTB-associated splicing factor (PSF), effectively inhibits PSF-lncRNA interaction and inhibits PSF target gene expression at the mRNA level.
PSF inhibitor No. 10-3 inhibits the PSF-mediated RNA splicing and the epigenetic pathway that promotes apoptosis and inhibits cell cycle in both breast and prostate cancer cells.
PSF inhibitor No. 10-3 potently inhibits the interaction of PSF with CTBP1-AS probe with IC50 of 2.2 pM.
PSF inhibitor No. 10-3 effectively induces apoptosis in these treatment-resistant cancer cells, inhibits prostate cancer cell proliferation (IC50 = 1.2 μmol/L, 22Rv1 cells).
PSF inhibitor No. 10-3 blocks the process of transcribed RNA to be spliced into mRNA.
PSF inhibitor No. 10-3 (5 mg/kg, five times per week) exhibits tumor growth inhibition in xenograft models of AR-positive 22Rv1 cells with no significant toxic effect, shows remarkably enhanced histone acetylation and cleaved PARP.
PSF functions as an epigenetic modifier by interacting with long noncoding RNAs and the corepressor complex. PSF also promotes RNA splicing events to enhance oncogenic signals.